

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC17 Rec'd PCT/PTO 1 0 JUN 2005

In re application of: Chung-Il HONG et al.

70

H

Int'l Application No.: PCT/KR2003/002700

Int'l Filing Date: December 10, 2003

Art Unit: Not Yet Assigned

Appl. No.: Not Yet Assigned

Examiner: Not Yet Assigned

Confirmation No.: Not Yet Assigned

mer. Trot Terrisong...e

Filed: June 10, 2005

Atty. Docket No.: 36470-218722

For: ORAL FORMULATIONS FOR

26694

POORLY ABSORPTIVE HYDROPHILIC DRUGS

Information Disclosure Statement

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Attention: PCT DO/EO/US

Sir

This is an Information Disclosure Statement submitted within the time limit specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of documents A1-A21which are listed on the attached Form PTO/SB/08A. The Examiner may deem these documents relevant to the patentability of the claims of the above-identified application. Documents A1-A8 are not being provided. Copies of A20 and A21 will be submitted in the near future.

The relevance of documents A1-A6 and A9-A17 is indicated in the above-referenced application. The relevance of documents A7-A8 and A18-A19 is indicated in the attached International Search Report of International Application No. PCT/KR2003/002700.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant(s): Chung-Il HONG et al. Int'l Appl. No.: PCT/KR2003/002700

In view of the above, no further translation or statement of relevance is required.

Additionally, since all requirements of 37 C.F.R. § 1.97 and all official guidelines pertaining to Information Disclosure Statements have been met, it is respectfully requested that the documents be considered by the Examiner and made of record.

Please charge any necessary fee, or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,

Marina V. Schneller

Registration No. 26,032 VENABLE LLP

P.O. Box 34385

Washington, D.C. 20043-9998 Telephone: (202) 344-4000 Telefax: (202) 344-8300

MVS/cdw 652718

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet of 1

Complete if Known				
Application Number	Not Y Lighe 5 3 6 8 6			
Filing Date	June 10, 2005			
First Named Inventor	Chung-11 HONG et al.			
Group Art Unit	Not Yet Assigned			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	36470-218722			

U.S. PATENT DOCUMENTS						
U.S. Patent Oocument		Name of Palentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevan		
Examiner Initials *	No.1	Number Kind (of Cited Document	Cited Document MM-OD-YYYY	Passages or Relevant Figures Appear
/C.S./	Al	3,882,243		Tadao MAEDA et al.	05-06-1975	
1	A2	2002/0015730	A1	Torsten HOFFMANN et al.	02-07-2002	
	A3	5,929,027	A	Shigeyuki TAKAMA et al.	07-27-1999	
\top	A4	5,665,711	A	Atsushi SAKAI et al.	09-09-1997	
\neg	A5	5,318,781	A	Navnit SHAH et al.	06-07-1994	
1/	A6	4,397,951		Kazuo TAKI et al.	08-09-1983	
$\neg V$	A7	6,184,037	BI	Alain ROLLAND et al.	02-06-2001	
/C.S./	A8	6,200,602	BI	Peter James WATTS et al.	03-13-2001	

			F	OREIGN	PATENT DOCU	MENTS		
	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
	No.1	Office ³	Number⁴ Kir	nd Code ⁵ (if known)	Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	T,
/C.S./	A9	DE	40 03 844	Ai		08-16-1990		
$\overline{}$	A10	EP	0 230 332	Al		07-29-1987		
	All	KR	2001-004208	3		05-25-2001	w/English Abstract	
	A12	KR	103209			04-22-1988	w/English Abstract	
	A13	WO	00/25598	Aì		05-11-2000		
_	A14	WO	94/25062	Ai		11-10-1994		
	A15	KR	026778	Bi		12-14-1983	w/English Abstract	
1	A16	EP	0 983 769	Aì		03-08-2000		
\neg	A17	EP	0 702 958	Ai		03-27-1996		
1/	A18	KR	2001-000636	1		01-26-2001	w/English Abstract	
W	A19	KR	020298	Bi		12-03-1982	w/English Abstract	
/C.S./	A20	WO	98/01159	A2		01-15-1998		

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/C.S./	A21	E.S. SWENSON et al., (C) MEANS TO ENHANCE PENETRATION, (2) INTESTINAL PERMAEBILITY ENHANCEMENT FOR PROTEINS, PEPTIDES AND OTHER POLAR DRUGS: MECHANISMS AND POTENTIAL TOXICITY, Advanced Drug Delivery Reviews, 1992, Vol. 8, No. 1, Pages 39-92.	

Examiner Signature	/Christopher Stone/	Date Considered	06/03/2008

to place a check mark here if English language Translation is attached. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



and not considered. Include copy of this form with next communication to applicant. 1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is